Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer

期刊论文
出版模式：

开放获取
发表日期：

2024年10月10日

查看全文

Nadia Øgaard,
Sarah Østrup Jensen,
Mai-Britt Worm Ørntoft,
Christina Demuth,
Mads Heilskov Rasmussen,
Tenna Vesterman Henriksen,
Jesper Nors,
Amanda Frydendahl,
Iben Lyskjær,
Marijana Nesic,
Christina Therkildsen,
Jakob Kleif,
Mikail Gögenur,
Lars Nannestad Jørgensen,
Jesper Vilandt,
Jakob Benedict Seidelin,
Kåre Anderson Gotschalck,
Claudia Jaensch,
Berit Andersen,
Uffe Schou Løve,
Ole Thorlacius-Ussing,
Per Vadgaard Andersen,
Thomas Kolbro,
Alessio Monti,
Jeppe Kildsig,
Peter Bondeven,
Nis Hallundbæk Schlesinger,
Lene Hjerrild Iversen,
Morten Rasmussen,
Ismail Gögenur,
Jesper Bertram Bramsen,
Claus Lindbjerg Andersen

摘要

Background

Multiple initiatives aim to develop circulating tumour DNA (ctDNA) tests for early cancer detection in asymptomatic individuals. The few studies describing ctDNA-testing in both asymptomatic and symptomatic patients report lower ctDNA detection in the asymptomatic patients. Here, we explore if asymptomatic patients differ from symptomatic patients e.g. by including a ‘low-ctDNA-shedding’ and ‘less-aggressive’ subgroup.

Methods

ctDNA assessment was performed in two independent cohorts of consecutively recruited patients with asymptomatic colorectal cancer (CRC) (Cohort#1: n = 215, Cohort#2: n = 368) and symptomatic CRC (Cohort#1: n = 117, Cohort#2: n = 722).

Results

After adjusting for tumour stage and size, the odds of ctDNA detection was significantly lower in asymptomatic patients compared to symptomatic patients (Cohort#1: OR: 0.4, 95%CI: 0.2–0.8, Cohort#2: OR: 0.7, 95%CI: 0.5–0.9). Further, the recurrence risk was lower in asymptomatic patients (Cohort#1: sHR: 0.6, 95%CI: 0.3–1.2, Cohort#2: sHR: 0.6, 95%CI: 0.4–1.0). Notably, ctDNA-negative asymptomatic patients had the lowest recurrence risk compared to the symptomatic patients (Cohort#1: sHR: 0.2, 95%CI: 0.1–0.6, Cohort#2: sHR: 0.3, 95%CI: 0.2–0.6).

Conclusions

Our study suggests that asymptomatic patients are enriched for a ‘low-ctDNA-shedding-low-recurrence-risk’ subgroup. Such insights are needed to guide ctDNA-based early-detection initiatives and should prompt discussions about de-escalation of therapy and follow-up for ctDNA-negative asymptomatic CRC patients.